Content » Vol 53, Issue 6

Double-blind trial of miconazole in dermatomycosis

Else Svejgaard
DOI: 10.2340/0001555553497499


A double-blind study of miconazole (Brentan®) has been performed in 86 patients suffering from dermatomycosis. Of the 65 patients not lost to follow-up, 30 had received the active drug, and 35 placebo. The cure-rate was significantly (p=0.03) higher in patients receiving miconazole (70%) than in those on placebo (40%). The higher cure-rate was found in patients suffering from cutaneous candidiasis and tinea versicolor, as well as from dermatophytosis, but was significant only in the latter group, which was the largest.


Supplementary content


Not logged in! You need to login/create an account to comment on articles. Click here to login/create an account.